Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma
Background Neutrophils play a controversial role in tumor development. The function of programmed cell death-1 ligand (PD-L1+) neutrophils, however, may inhibit the cytotoxicity of anti-tumor immunity. In this study, we elucidate the stimulators of PD-L1+ neutrophils in tumor microenvironment (TME)...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-06-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/9/6/e002305.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850196914035752960 |
|---|---|
| author | Ming Zhao Qifeng Chen Wenhua Lu Ning Lyu Zhenfeng Zhang Qiankun Xie Haijing Deng Anna Kan Meng He Shuang Qiao Shaolong Li Huiming Chen Jinfa Lai Xiongying Jiang Shousheng Liu |
| author_facet | Ming Zhao Qifeng Chen Wenhua Lu Ning Lyu Zhenfeng Zhang Qiankun Xie Haijing Deng Anna Kan Meng He Shuang Qiao Shaolong Li Huiming Chen Jinfa Lai Xiongying Jiang Shousheng Liu |
| author_sort | Ming Zhao |
| collection | DOAJ |
| description | Background Neutrophils play a controversial role in tumor development. The function of programmed cell death-1 ligand (PD-L1+) neutrophils, however, may inhibit the cytotoxicity of anti-tumor immunity. In this study, we elucidate the stimulators of PD-L1+ neutrophils in tumor microenvironment (TME) and explore the optimal combination to enhance the effect of lenvatinib by inhibiting PD-L1+ neutrophils in hepatocellular carcinoma.Methods Neutrophil infiltration after lenvatinib treatment was examined with RNA sequencing and multicolor flow cytometry analysis in patient samples, subcutaneous and orthotopic mouse models. Neutrophils and T cells were isolated from peripheral blood and tumor tissues and purified with magnetic beads for cytotoxicity assay. Metabolites and cytokines were detected by a biochemical analyzer manufactured by Yellow Springs Instrument (YSI) and proteome profiler cytokines array. In vitro screening of pathway inhibitors was used to identify possible candidates that could reduce PD-L1+ neutrophil infiltration. Further in vivo assays were used for verification.Results Lenvatinib increased neutrophil recruitment by inducing CXCL2 and CXCL5 secretion in TME. After entering TME, neutrophils polarized toward N2 phenotype. PD-L1 expression was simultaneously upregulated. Thus, lenvatinib efficacy on tumor cells hindered. The increasing PD-L1+ neutrophils positively corelated with a suppressive T cell phenotype. Further investigation indicated that JAK/STAT1 pathway activated by immune-cell-derived interferon γ and MCT1/NF-kB/COX-2 pathway activated by high concentrations of tumor-derived lactate could induce PD-L1+ neutrophils. The latter could be significantly inhibited by COX-2 inhibitor celecoxib. Further in vivo assays verified that Celecoxib decreased the survival of lactate-stimulated PD-L1+ neutrophil and promoted the antitumor effect of lenvatinib.Conclusions PD-L1+ neutrophils decrease T cell cytotoxicity. Tumor-derived lactate induces PD-L1 expression on neutrophils via MCT1/NF-κB/COX-2 pathway. Thus, COX-2 inhibitor could reduce PD-L1+ neutrophil and restore T cell cytotoxicity. This may provide a potent addition to lenvatinib. |
| format | Article |
| id | doaj-art-a8727dadc0ff402fa3eb3d40ae114036 |
| institution | OA Journals |
| issn | 2051-1426 |
| language | English |
| publishDate | 2021-06-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-a8727dadc0ff402fa3eb3d40ae1140362025-08-20T02:13:19ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262021-06-019610.1136/jitc-2020-002305Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinomaMing Zhao0Qifeng Chen1Wenhua Lu2Ning Lyu3Zhenfeng Zhang4Qiankun Xie5Haijing Deng6Anna Kan7Meng He8Shuang Qiao9Shaolong Li10Huiming Chen11Jinfa Lai12Xiongying Jiang13Shousheng Liu143 Department of Dermatology, Hunan Key Laboratory of Medical Epigenomics, The Second Xiangya Hospital of Central South University, Changsha, ChinaState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, ChinaState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, ChinaState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, ChinaMinimally Invasive Interventional Division, Guangzhou Medical University Second Affiliated Hospital, Guangzhou, Guangdong, ChinaDepartment of Radiation Oncology, Southern Hospital of Southern Medical University, Guangzhou, Guangdong, ChinaMinimally Invasive Interventional Division, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, ChinaState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China1 Department of Radiology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital, Beijing, ChinaState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, ChinaState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, ChinaState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, ChinaState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, ChinaInterventional Radiology Divison, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, ChinaState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, ChinaBackground Neutrophils play a controversial role in tumor development. The function of programmed cell death-1 ligand (PD-L1+) neutrophils, however, may inhibit the cytotoxicity of anti-tumor immunity. In this study, we elucidate the stimulators of PD-L1+ neutrophils in tumor microenvironment (TME) and explore the optimal combination to enhance the effect of lenvatinib by inhibiting PD-L1+ neutrophils in hepatocellular carcinoma.Methods Neutrophil infiltration after lenvatinib treatment was examined with RNA sequencing and multicolor flow cytometry analysis in patient samples, subcutaneous and orthotopic mouse models. Neutrophils and T cells were isolated from peripheral blood and tumor tissues and purified with magnetic beads for cytotoxicity assay. Metabolites and cytokines were detected by a biochemical analyzer manufactured by Yellow Springs Instrument (YSI) and proteome profiler cytokines array. In vitro screening of pathway inhibitors was used to identify possible candidates that could reduce PD-L1+ neutrophil infiltration. Further in vivo assays were used for verification.Results Lenvatinib increased neutrophil recruitment by inducing CXCL2 and CXCL5 secretion in TME. After entering TME, neutrophils polarized toward N2 phenotype. PD-L1 expression was simultaneously upregulated. Thus, lenvatinib efficacy on tumor cells hindered. The increasing PD-L1+ neutrophils positively corelated with a suppressive T cell phenotype. Further investigation indicated that JAK/STAT1 pathway activated by immune-cell-derived interferon γ and MCT1/NF-kB/COX-2 pathway activated by high concentrations of tumor-derived lactate could induce PD-L1+ neutrophils. The latter could be significantly inhibited by COX-2 inhibitor celecoxib. Further in vivo assays verified that Celecoxib decreased the survival of lactate-stimulated PD-L1+ neutrophil and promoted the antitumor effect of lenvatinib.Conclusions PD-L1+ neutrophils decrease T cell cytotoxicity. Tumor-derived lactate induces PD-L1 expression on neutrophils via MCT1/NF-κB/COX-2 pathway. Thus, COX-2 inhibitor could reduce PD-L1+ neutrophil and restore T cell cytotoxicity. This may provide a potent addition to lenvatinib.https://jitc.bmj.com/content/9/6/e002305.full |
| spellingShingle | Ming Zhao Qifeng Chen Wenhua Lu Ning Lyu Zhenfeng Zhang Qiankun Xie Haijing Deng Anna Kan Meng He Shuang Qiao Shaolong Li Huiming Chen Jinfa Lai Xiongying Jiang Shousheng Liu Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma Journal for ImmunoTherapy of Cancer |
| title | Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma |
| title_full | Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma |
| title_fullStr | Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma |
| title_full_unstemmed | Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma |
| title_short | Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma |
| title_sort | tumor derived lactate inhibit the efficacy of lenvatinib through regulating pd l1 expression on neutrophil in hepatocellular carcinoma |
| url | https://jitc.bmj.com/content/9/6/e002305.full |
| work_keys_str_mv | AT mingzhao tumorderivedlactateinhibittheefficacyoflenvatinibthroughregulatingpdl1expressiononneutrophilinhepatocellularcarcinoma AT qifengchen tumorderivedlactateinhibittheefficacyoflenvatinibthroughregulatingpdl1expressiononneutrophilinhepatocellularcarcinoma AT wenhualu tumorderivedlactateinhibittheefficacyoflenvatinibthroughregulatingpdl1expressiononneutrophilinhepatocellularcarcinoma AT ninglyu tumorderivedlactateinhibittheefficacyoflenvatinibthroughregulatingpdl1expressiononneutrophilinhepatocellularcarcinoma AT zhenfengzhang tumorderivedlactateinhibittheefficacyoflenvatinibthroughregulatingpdl1expressiononneutrophilinhepatocellularcarcinoma AT qiankunxie tumorderivedlactateinhibittheefficacyoflenvatinibthroughregulatingpdl1expressiononneutrophilinhepatocellularcarcinoma AT haijingdeng tumorderivedlactateinhibittheefficacyoflenvatinibthroughregulatingpdl1expressiononneutrophilinhepatocellularcarcinoma AT annakan tumorderivedlactateinhibittheefficacyoflenvatinibthroughregulatingpdl1expressiononneutrophilinhepatocellularcarcinoma AT menghe tumorderivedlactateinhibittheefficacyoflenvatinibthroughregulatingpdl1expressiononneutrophilinhepatocellularcarcinoma AT shuangqiao tumorderivedlactateinhibittheefficacyoflenvatinibthroughregulatingpdl1expressiononneutrophilinhepatocellularcarcinoma AT shaolongli tumorderivedlactateinhibittheefficacyoflenvatinibthroughregulatingpdl1expressiononneutrophilinhepatocellularcarcinoma AT huimingchen tumorderivedlactateinhibittheefficacyoflenvatinibthroughregulatingpdl1expressiononneutrophilinhepatocellularcarcinoma AT jinfalai tumorderivedlactateinhibittheefficacyoflenvatinibthroughregulatingpdl1expressiononneutrophilinhepatocellularcarcinoma AT xiongyingjiang tumorderivedlactateinhibittheefficacyoflenvatinibthroughregulatingpdl1expressiononneutrophilinhepatocellularcarcinoma AT shoushengliu tumorderivedlactateinhibittheefficacyoflenvatinibthroughregulatingpdl1expressiononneutrophilinhepatocellularcarcinoma |